

Index

- Accelerated death benefits, 165
- Accountants:
A.M. Best's analysis and, 69
role in securitization, 53
- Acquisition schedule, A.M. Best's analysis and, 75
- Actual to Expected analysis, in underwriting, 28
- Actuaries, roles of, 21–22, 52
- Adviser for inconsistency, role in securitization, 51
- Age:
age 105 and risk, 161
pricing and, 96
risk and misstatement of, 161
- AIDS, 3–4, 199
- AIG, 112
- Allianz Life, 165
- Alpha-longevity risk, 180–193
buying strategies, 185–187
- A.M. Best Co., 50, 230, 239, 241
analysis based on existing portfolio, 55–56
analysis based on newly acquired portfolio, 53–55
description of life settlement market, 14
evaluating credit risk, 79–89
evaluating settlement-backed securities, 56–79
security surveillance, 90–91
transaction costs and, 16, 65–66
- American Council of Life Insurers (ACLI),
holding period proposal, 135–150
costs of, 135, 137, 142, 143–145
insurance industry and, 216–217
real options analysis framework, 137–148
- American puts, 141, 142
- Analytics and pricing:
duration and complexity valuation, 109–134
life settlement pricing, 95–108
real options approach to valuation and ACLI five-year holding period proposal, 135–150
- Angel, Linda, 204
- Annuities:
annuity mortality tables, 30
annuity unwind, 161
profit motive and, 235–236
- Arrangers of transactions, A.M. Best's analysis and, 69
- Asset services, 23–24
- Attorneys:
A.M. Best's analysis and, 66–67
role in securitization, 53
- Auditors:
A.M. Best's analysis and, 69
role in securitization, 53
- Aurora Defined Benefits Fund, 115
- AVS Underwriting, 22
- AXA Equitable Life Insurance Company, 203–204
- Backup service providers, A.M. Best's analysis and, 68–69
- Basis in property, tax issues and, 227–228
- Beneficial interest:
defined, 5–6
regulation and, 200
- Beneficiary, defined, 5
- Bernstein Research, 135–136, 238, 240
- Beta-longevity risk, 181–193
- Brackenridge's Medical Selection of Life Risks* (Brackenridge, Croxson, and Mackenzie), 58
- Brokers, role in transactions, 20, 112
- Business planning, as reason for sale of life insurance, 13

- Cantor Life Markets, 24
- Carrier approved premium finance, 45
- Cash value, pricing and, 97
- Cell companies, 115
- Closed-end funds, 115
- Cohen v. Comm'r*, 227
- Collateral manager:
 - A.M. Best's analysis and, 67–68
 - role in securitization, 51
- Commissioners' Standard Ordinary mortality table ('80 CSO), 29
- Commissions, disclosure of broker's, 20
- Contestability period, 6, 11
 - regulation and, 199–200, 216–218
 - risk mitigation and, 155–156
- Controlled foreign corporation (CFC), 229
- Convertible Term Life Insurance policies, 9
- Cost of insurance (COI), risk mitigation and, 157–158
- Coventry, 19, 113
- Credit markets, pricing and, 98
- Credit Suisse Longevity Indexsm, 188
- Death benefits, recovery after impairment, 80–81
- Debit default table, 82
- Debit methodology, in underwriting, 25–26
 - A.M. Best's analysis and, 57–59
- Debt rating, by A.M. Best, 53, 55
- Derivatives. *See* Synthetic longevity assets
- Deterministic pricing model, 100–101
- Discounted cash flow, pricing and, 98–99
- Diversity of policies:
 - A.M. Best's analysis and, 71–72
 - risk mitigation and, 159–160
- Documentation, A.M. Best's analysis and, 77–78
- Doherty, N., 136
- Eastport Financial, LLC., 112
- EEA Life Settlement Fund, 115
- '80 CSO, 29
- Electronic exchanges, 24
- EPIC Life Settlement Fund, 118
- Equity capital, risk and, 153–155, 160
- Estate planning:
 - premium financing and, 43
 - as reason for sale of life insurance, 12–13
- Estate taxes, 225
- Ethical issues, 235–244
 - best practice standards for intermediaries, 237–238
 - clear and consistent regulation, 239–241, 242
 - fair treatment of policy holders, 237, 242
 - market inefficiencies and, 235–236
 - policy sale and, 13
 - proposals for, 241–243
 - transparency for investors, 238–239, 242
- European puts, 141–142
- Exchanges, 24
- Existing portfolio, A.M. Best's analysis of, 55–56
- Experience mortality tables, 29
- Face-value variance risk, 180
- Fasano Associates, 22
- Females, mortality tables and, 31, 33
- Financial Accounting Standards Board (FASB), 114
- Financial advisers, 17
- Financial Industry Regulatory Authority (FINRA), 206–207
- Financing entities, 20–21
- Five-year holding period, proposed by ACLI, 135–150
 - costs of, 135, 137, 142, 143–145
 - insurance industry and, 216–217
 - real options analysis framework, 137–148
- Florida, 203
- Forbes Lithograph Mfg. Co. v. White*, 227
- Foreign holders, tax issues, 228–230
- Franklin Templeton Total Return Fund, 110–111
- Full recourse premium financing, 43–44
- Funders computations, 34–37
- Gain, tax issues and character of, 226–227
- Global Insurance Exchange, 24
- Goldman Sachs, 129, 131
- Grigsby v. Russell*, 3, 199
- Group mortality tables, 29
- Health Insurance Portability and Accountability Act (HIPAA), 70
- Hedge funds, 112
- Hedging longevity risk, 187–189
- Holmes, Oliver Wendell, 3

- Howie test, 205–206
- Hybrid synthetic assets, 246–247
- ICAP markets, 188–189
- Impairment risk, A.M. Best’s analysis and, 80–82
- Income protection, as reason for sale of life insurance, 12
- Inconsistency checks, 51
- Incorrect purchase price, 158
- Indiana, 240
- Indicative rating, by A.M. Best, 53–55, 75
- Institutional Life Markets Association, Inc. (ILMA), 4, 208
- Institutional Life Services, 24
- Insurable interest, 66–67
 - regulation and, 198–199
 - risk and, 156–157
- Insurance companies
 - alpha-longevity risk and, 185–187
 - credit risk and, 159
 - impact of secondary market on, 243
 - longevity swaps and, 192
 - rate of claims, 153–154
 - ratings and pricing, 97
 - reactions to regulatory framework, 197–212
 - reactions to regulatory issues, 213–224
 - role in securitization, 52–53
 - viatical settlements and, 213–215
- Insurance policies, 5–9
 - A.M. Best’s analysis and types of, 56–57, 71–72, 75–76
 - beneficial interest, 5–6
 - contestability period, 6
 - policy swaps, 39–41
 - pricing and size of, 98
 - types of policies, 6–9
- Insured, defined, 5
- Interest deductions, tax issues, 228–229
- Interest rates:
 - policy swaps and, 39–40
 - premium financing and, 44
 - risk and interest gap, 161
- Intermediaries, 15
 - ethics and best practices, 237–238
- Internal rate of return (IRR), synthetic assets and, 252–253
- Investors:
 - ethics and transparency for, 238–239, 242
 - role in transactions, 20–21
- Irrevocable life insurance trust (ILIT), 43, 200, 201
- Issuer, role in securitization, 53
- Joint survivorship policies, pricing and, 96–97
- J.P. Morgan, 129, 131, 188
- Key-man insurance, 13
- King, Larry, 206–207
- Lansdowne Atlantic Life Settlement Fund, PLC, 118–119
- Law of Large Numbers, risk and, 153–154
- LE-duration and LE-convexity:
 - methodologies, 116–117, 119–131
 - model, 172–175
- Legacy Benefits, 19
- Legal reviews, A.M. Best’s analysis and, 78
- Level versus varying mortality ratio, 36–37
- Licensing, of providers, 19
 - A.M. Best’s analysis and, 66–67
- Life Exchange, Inc., 24, 111–112
- Life expectancy. *See also* Underwriting
 - duration and convexity, 163–177
 - LE-duration and LE-convexity model, 172–175
 - Lifemark Secure Income Bond, 167–171
 - Macauley duration D, 175–176
 - pricing and, 96
- Life expectancy (LE) providers, 34–37
- Life-extension risk (longevity risk), 109–110, 117, 159–162
- Life Insurance Settlement Association, 4
- Lifeline Program, 20
- Lifemark Secure Income Bond, 167–171
- LifeMetrics Indexsm, 129, 131, 188
- Life Partners Holdings, Inc., 112, 113–114, 164
- Life Settlement Fund Series A, 112
- Life settlements, 11–12
 - description of market, 14
 - history of, 3–4
 - parties involved in, 17–24, 50–53
 - reasons for purchase of policies, 12–14
 - reasons for sale of policies, 12–13, 49–50
 - returns on, 15–16

- Life Settlements Institute (LSI), 240–241
“Life Settlements Market: An Actuarial Perspective on Consumer Economic Value, The,” 117–118
Life Settlement Solutions, Inc., 19, 112–113
Limited recourse premium financing, 44, 46
Liquidation plan, A.M. Best’s analysis and, 77
Liquidation prospects, A.M. Best’s analysis and, 73–74, 82
Liquidity risk, 117
Loans:
 premium financing and, 44–45
 pricing and, 97–98
 tax implications, 229–230
Lobel, Leon, 204
Loews Corporation, 112
Longevity-extension insurance, 187–189
Longevity risk, 109–110, 117, 159–162
Longevity swap, 246
Long-term debt rating, by A.M. Best, 53, 55
- Macaulay duration D, 175–176
Males, mortality tables and, 31, 32–33
Management expertise, A.M. Best’s analysis and, 77
Maple Life, 136
Market disruptions, risk and, 161
Medical examiners:
 A.M. Best’s analysis and, 57–64, 69–70, 79
 role in securitization, 51
Medical Information Bureau (MIB), 25
Medical records, A.M. Best’s analysis and, 69–71
Minnesota, 203
Missing body risk, 158–159
Modified debit methodology, in underwriting, 26–27
Modified endowment contracts (MECs), 225
Monte Carlo simulations, 82–89
 in stochastic pricing model, 103–108
Mortality. *See* Underwriting
- National Association of Insurance Commissioners (NAIC), 202, 215, 239–240
 model act, 201–202, 215–218
 model act, contrasted to NCOIL’s, 220
- National Association of Securities Dealers (NASD), 206–207
National Conference of Insurance Legislators (NCOIL), 201, 215
 model act, 202, 218–220
 model act, contrasted to NAIC’s, 220
Net present value:
 pricing and, 98–99
 synthetic assets and, 183–184, 252–253
Newly acquired portfolio, A.M. Best’s analysis of, 53–55
New Stream Capital, 112
New York, 156, 204
Nonconvertible policies, pricing and, 96
Nonrecourse premium financing, 44, 46
Nonsmokers, mortality tables and, 31, 33
North Dakota, 220
“Notice to Members” (FINRA), 206–207
Ohio, 240
Open-ended funds, 115
Partial recourse premium financing, 44, 46
Passive foreign investment company (PFIC), 229
Peachtree Life Settlements, 19
Pensioenfonds Metalektro, 112
Permanent life insurance, 6–9
Phoenix Life Insurance Company, 204
Phoenix Life Solutions, 208
Policies. *See* Insurance policies
Policyholders:
 defined, 5
 ethics and treatment of, 237, 242
Policy in-force period, A.M. Best’s analysis and, 70–71
Prearranged life settlements, regulatory issues, 202–204
Preliminary assessment, by A.M. Best, 53–54
Premium financing, 43–46
 regulation and, 216
 types of, 43–44
Premiums:
 payment of, 23–24
 pricing, 97–98
 risk mitigation and, 158–159, 161
Pricing, 95–108
 A.M. Best’s analysis and, 74–75
 deterministic model, 100–101
 discounted cash flow and net present value, 98–99

- policy value drivers, 95–98
- probabilistic model, 101–103
- risk and incorrect purchase price, 158
- stochastic model, 103–108
- Private Client Portfolio, 115
- Probabilistic pricing model, 101–103, 251
- Property casualty coverage, risk mitigation and, 162
- Providers:
 - A.M. Best’s analysis and, 65–66
 - role in securitization, 51
 - role in transactions, 17–20
- Q Capital Strategies, 19–20
- Qualified institutional buyer (QIB), 21
- QxX.LS index, 129, 131
- Racketeer Influence and Corrupt Organizations Act (RICO), 204
- Rate of claims (ROC), of insurance companies, 153–154
- Real options framework, for valuation, 135–150
 - ability to resell and, 138–140
 - ACLJ’s five-year holding period proposal, 135–137
 - valuing of option to resell, 140–141
 - valuing of option to resell, as American puts, 141, 142
 - valuing of option to resell, as European puts, 141–142
- Reference mortality experience, 58
- Regulation. *See also* Tax issues
 - ethics and, 239–241, 242
 - framework and insurance company reactions, 197–212
 - issues and insurance company reactions, 213–224
- Regulatory valuation tables, 29
- Research-based clinical judgment, in underwriting, 27–28
- Residual value, 73
- Retirement planning, as reason for sale of life insurance, 13
- Return on traded policy, 15–16
- Risk management:
 - A.M. Best’s analysis and, 72–74, 79–89
 - applying LE-duration and LE-convexity methodologies to, 119–131
 - life expectancy and, 163–177
 - risk mitigation, 153–162
 - synthetic assets and, 179–183
 - underwriting strategies, 37
- Sales documentation, A.M. Best’s analysis and, 66–67
- Secondary Life Capital, 20
- Securities law, 204–207
- Securitization, 49–91
 - A.M. Best’s approach to credit evaluation, 79–89
 - A.M. Best’s approach to securities evaluation, 56–79
 - A.M. Best’s rating policies, 53–56
 - A.M. Best’s surveillance requirements, 90–91
- SEC v. Life Partners, Inc.*, 205
- SEC v. Mutual Benefits Corp.*, 205–206
- Select mortality rates, 30–32
- Senior life settlements, 166–167
- Sex, risk and misstatement of, 161
- Silverman, R., 136
- Singer, Hal J., 118, 136
- Single Premium Immediate Annuity (SPIA), 44, 45
- Smokers, mortality tables and, 31, 33
- Socially responsible investment (SRI) strategy, 242
- Society of Actuaries (SoA), 29, 30
- Source of income, tax issues, 228
- Stallard, Eric, 118, 136
- Stalsberg v. New York Life Insurance Company*, 203–204
- Stochastic pricing model, 103–108
- Stone, Charles A., 119, 172–175
- Stop-loss insurance, 73
- Stranger-owned life insurance (STOLI), 6, 44, 211, 237, 240
 - regulation and, 200–202, 214–215
 - state legislation and, 221–223
- Surrender values, 13–14
- Surveillance requirements, A.M. Best analysis and, 90–91
- Swaps, synthetic, 179–193, 246
 - benefits of, 189–193
- SwapsMarketsm, 188–189
- Synthetic longevity assets, 208, 238, 245–253
 - advantages of, 247–249
 - ethics proposals and, 243

- Synthetic longevity assets (*Continued*)
swaps to hedge longevity risks, 179–193
types of, 246–247
underlying lives and, 250–251
valuation of, 251–253
- Table bias, 183–184
- Tax issues:
ACLI proposal, 137, 149
A.M. Best’s analysis and, 77–78
open issues, 226–228
policy swaps and, 39–41
regulations and, 225–231
viatical settlements, 4
- 1035 exchanges, 46
- Term life insurance, 6–7, 12
pricing and, 96
profit and, 236
- Tracking agent:
A.M. Best’s analysis and, 67
role in securitization, 51
- Traded life policy (TLP), 11
- Transaction costs, 16, 65–66
- Transamerica Life Solutions, LLC, 208
- Transfer of policy, A.M. Best’s analysis and,
70–71
- Trustee, role in securitization, 52
- 21st Services, 22
- 2001 Valuation Basic Table (2001VBT), 29,
30
A.M. Best’s analysis and, 58, 61, 73, 79
- 2008 Valuation Basic Tables (2008VBT), 29,
239
- Ultimate mortality rates, 30–32
- Underwriting, 25–37
A.M. Best’s analysis and mortality matrix,
82–89
contrasted to life insurance underwriting,
25–26
life expectancy, 31–34
medical examiners and A.M. Best analysis,
57–64
methodologies, 26–28
mortality tables, 29–30
performance measurement, 28
risk management strategies, 37
role of underwriters, 21–22
select and ultimate mortality rates,
30–32
- Universal American Financial Corp.,
163–164
- Universal Life insurance policies, 7, 96
- Utah, 203
- Utopia TLP Fund, PLC, 115–116
- Valuation, of contracts, 109–134. *See also*
Real option framework, for valuation
accounting rules, 114–115
LE-duration and LE-convexity
methodologies, 119–131
structure of market and, 111–119
synthetic assets, 251–253
- Variable Life insurance policies, 7
- Variable Universal Life (VUL) Insurance
policies, 7, 9, 206
- Via Source, 115
- Viatical settlements, 3–4, 14, 49–50, 111,
199, 213–215
- vivaDexsm, 188–189
- “Wet paper,” 6
- Whole Life insurance policies, 7, 12, 97
- Zissu, Anne, 119, 172–175

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>